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ABSTRACT
Motivation: Current microarray analyses focus on identifying sets
of genes that are differentially expressed (DE) or differentially
coexpressed (DC) in different biological states (e.g. diseased versus
non-diseased). We observed that in many human diseases, some
genes have a signiﬁcant increase or decrease in expression variability
(variance). As these observed changes in expression variability may
be caused by alteration of the underlying expression dynamics, such
differential variability (DV) patterns are also biologically interesting.
Results: Here we propose a novel analysis for changes in
gene expression variability between groups of samples, which
we call differential variability analysis. We introduce the concept
of differential variability (DV), and present a simple procedure
for identifying DV genes from microarray data. Our procedure
is evaluated with simulated and real microarray datasets. The
effect of data preprocessing methods on identiﬁcation of DV
gene is investigated. The biological signiﬁcance of DV analysis is
demonstrated with four human disease datasets. The relationships
among DV, DE and DC genes are investigated. The results suggest
that changes in expression variability are associated with changes in
coexpression pattern, which imply that DV is not merely stochastic
noise, but informative signal.
Availability: The R source code for differential variability analysis is
available from the contact authors upon request.
Contact: joshua@it.usyd.edu.au; mcharleston@it.usyd.edu.au
1 INTRODUCTION
Microarray technology enables the expression level of all or most of
thegenesinthegenometobemeasuredsimultaneously.Suchglobal-
scale gene expression proﬁling has revolutionized medical research
as we can now search for disease-related genes in a systematic and
unbiased manner. In a representative biomedical gene expression
proﬁling study, we generate and compare expression proﬁles taken
from tissue samples of a group of patients suffering from the same
disease and a group of non-diseased individuals. A typical analysis
involves identiﬁcation of differentially expressed (DE) genes that
may be associated with the disease.Arange of statistical procedures,
such as linear modeling (Smyth, 2004) and SAM (Tusher et al.,
2001), has been devised for accurate and efﬁcient identiﬁcation of
DE genes. In recent years, the community has also started to focus
on differential coexpression analyses (Choi et al., 2005; Kostka and
Spang, 2004; Watson, 2006), which aim to identify sets of genes
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that are always coexpressed in non-diseased individuals but not in
diseased individuals or vice versa. The differentially coexpressed
(DC) analysis is motivated by the observation that gene expression
across a group of individuals appears to be correlated, and such
coexpression patterns may differ in disease and non-disease states.
Both DE and DC analyses have been successful in identifying
novel disease-related genes and generating new hypotheses about
the molecular events related to pathogenesis (e.g. Choi et al., 2005).
In this article, we present a new type of microarray analysis called
differential variability (DV) analysis. Traditional DE analysis aims
to identify genes with signiﬁcant changes in mean expression level
between diseased and non-diseased samples, whereas DV analysis
aims to identify genes with a signiﬁcant change in variance of
expression between a group of diseased patients and non-diseased
individuals(seeFig.1foracomparisonofDE,DCandDVpatterns).
Pritchard et al. (2001) systematically studied gene expression
variability in normal mice and found a set of genes that have similar
expression levels among technical replicates but very different
expression levels among individual mice. Genes associated with
immune-modulation, stress and hormonal regulation are found
to have high expression variability. Such elevated degrees of
variability are accounted for by the heterogeneous amount of
regulatory signals present at the time of death (Pritchard et al.,
2001). Bahar et al. (2006) showed that some genes have increased
cell-to-cell gene expression variability in cardiomyocytes in older
mice compared with younger mice. They attributed the increase in
expression variability to stochastic deregulation of gene expression,
due to DNA damage accumulated during the life-time of a mouse.
Cheung et al. (2003) showed that genes of certain functional classes
have elevated expression variability in human lymphoblastoid
cells. In conjunction with our own observations of a large human
heart microarray dataset (Stefani et al., manuscript in preparation),
it appears that patterns of gene expression variability are also an
important area of study in human diseases.
The main contribution of this article is to formally introduce the
concept of DV analysis of gene expression, and to demonstrate
its applicability to human disease datasets. Both the technical
issues associated with the analysis and the biological signiﬁcance
of DV genes are discussed here. Speciﬁcally, we ﬁrst propose
asimpleF-test-basedprocedureforidentifyingDVgenesfromlarge
microarray datasets, and compare our method with a number of
more robust variants using simulated data (here ‘robust’ is used
to mean resistant to the effect of outliers). The effect of array
data preprocessing on the reliability of DV analysis is investigated.
In an analysis of four independent human disease datasets, we
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Fig. 1. An illustration of the concept of (a) DE, (b) DC and (c) DV. The
x-axesrepresentindividualsamplesandthey-axesrepresentgeneexpression
level.
verify that statistically signiﬁcant DV genes do exist and many
of them are relevant to the disease development. The relationships
among differential expression, coexpression and variability are also
investigated.
2 METHODS
2.1 Deﬁnition of differential variability
Here we propose a simple deﬁnition of differential variability of a gene
between two conditions.We ﬁrst assume that the true population distribution
oftheexpressionofagenexc inagivenconditionchasmeanµc andvariance
σ2
c . For any two conditions, we formulate a two-sided hypothesis test for
each gene: The null hypothesis H0:σ2
1 =σ2
2 versus the alternative hypothesis
H1:σ2
1  =σ2
2. If the null hypothesis is rejected based on some statistical test,
we call this gene differentially variable (DV). A gene that has differential
variability is called a DV gene.
2.2 F-test for differential variability analysis
To test for genes with signiﬁcant DV, we propose to use the F-test. For any
gene with n (log-)expression values in condition 1 and m (log-)expression
valuesincondition2,wecanbaseourtestonf =s2
1/s2
2 wheres2
1 ands2
2 arethe
sample variances of the expression values in condition 1 and 2, respectively.
If the expression of a gene is distributed normally, i.e. Xc∼N(µc,σ2
c ),
f follows an Fn−1,m−1 distribution under the null hypothesis. The P-value of
thistestis2×min(pr,1−pr)forpr=P(Fn−1,m−1≤ f).AlthoughtheF-testis
simple and is widely used to quantify differences in variance, it is sensitive
to deviation from the normality assumption or presence of outliers (e.g.
unexpectedly higher or lower expression values from one or two samples).
To overcome this shortcoming, an outlier removal step is performed before
the F-test, to eliminate those expression values that are signiﬁcantly higher
or lower than majority of the expression values. These so-called ‘outliers’
might indeed be true signals, so removal of those points might increase
the overall false-negative rate. However, we opt for this more conservative
approach as outliers can be analyzed separately. In this article, we use a
simple inter-quartile range (IQR) criterion to detect outliers. Given all the
expression values across the two conditions, we deﬁne Q1 and Q3 to be the
ﬁrst and third quartiles, and IQ=Q3−Q1 be the IQR. Any values that are
less than Q1−rIQ or greater than Q3+rIQ are labeled as outliers for any
r>0. Outliers are then removed, followed by adjusting m and n to reﬂect the
actual number of unﬁltered samples for the gene under consideration. We
used r=1.5 in this article because it achieves desirable ﬁltering properties
in practice.
Similar to any multiple testing problem, the P-value must be adjusted to
account for multiple comparisons. A range of adjustment procedures can
be used in this step, and we selected the false-discovery rate correction
method by Benjamini and Hochberg (1995) in our study. Finally, all the
genes with adjusted P-value below a pre-deﬁned signiﬁcance level α are
deemed differentially variably expressed. This procedure described here is
implemented in the R language (Ihaka and Gentleman, 1996).
Our DV identiﬁcation procedure can be summarized as follows:
(1) For each gene:
1.1 remove outliers using the IQR criteria. Adjust n and m if necessary;
1.2 compute f and its corresponding P-value.
(2) Adjust the P-value for multiple comparisons and mark any genes with
P ≤α as differentially variable.
2.3 Other differential variability measures
Although the F-test is a simple and intuitive test for DV analysis, its
robustnessagainstviolationofthenormalityassumptionneedsinvestigation.
In particular, our method relies on an outlier removal step, which effectively
reducesthevarianceandsamplesize.Also,theparameterr oftheIQRcriteria
is probably not the same for each gene and each dataset. We, therefore, seek
to develop other methods that can better handle potential outliers without
unnecessarily removing data. We developed a number of variant methods by
following two general approaches: (1) replace SD with other robust scale
estimators and (2) permutation tests.
TwovariantDVtestsareconstructedbyreplacingtheSD(s)bytworobust
scale estimators: median absolute deviation (MAD) and Qn (Rousseeuw and
Croux, 1993). MAD is the most widely used robust scale estimator due to
its simplicity and resistance to the effect of outliers. MAD is deﬁned as:
MAD=1.4826×median(|Xi−m|)
where m=median(Xi). The factor 1.4826 is used to make it consistent with
SD. Qn is another robust scale estimator which is deﬁned as
Qn=2.2219×{{|Xi−Xj|};i<j}(k)
where k=
[n/2]+1
2

. In other words, Qn is the k-th smallest value of all
|Xi−Xj|, for i<j. The factor 2.2219 is used to make it consistent with SD.
Since both MAD and Qn approximate s, the resulting f value should retain
the F(n−1)(m−1) distribution under the null hypothesis.
We also devised a number of tests based on permutation. Since we do not
have to rely on any known distribution, we can employ different statistics
from f. The f-statistic is based on the ratio of variance, but we may also test
the hypothesis by using statistics based on the difference of two variances, or
SDs. Hence, we developed three new statistics: (s1−s2), (MAD1−MAD2)
and (Qn1−Qn2). A permutation test is performed by randomly shufﬂing the
sample labels, then calculating the fraction of times the original statistic
is less or equal to the statistic generated by the permuted samples. In this
study, we perform 1000 permutation per gene. A total of eight differential
variability tests are developed (Table 1) and are evaluated using simulated
data (Section 2.4).
2.4 Evaluation with simulated data
WeevaluatedtheperformanceoftheeightDVtests(Table1)usingsimulated
microarray datasets with known DV structures. With a given mean µ and
varianceσ2,wesimulatedexpressionvaluesasindependentlyandidentically
distributed values from normal distribution N(µ,σ2), uniform distribution
U(µ−
√
3σ2,µ+
√
3σ2)andgammadistribution (µ2/σ2,µ/σ2).Inallour
tests,wesimulated40expressionproﬁleseachcontaining300genes.Among
the 40 proﬁles, 20 are assigned to be ‘normal’ and are simulated with µ=7
and σ2=6, while the other 20 ‘diseased’ proﬁles were simulated with µ=7
and σ2=12. The effect of outliers was simulated by randomly selecting one
array and multiplying all its expression values by 3. Using this simulation
scheme, eight differential variability tests were evaluated (Table 1). The
proportion of genes identiﬁed as DV was calculated for each method. With
a signiﬁcance level of 0.01, we would expect a good DV tests to make
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Table 1. Summary of the eight tests of differential variability
Test Statistic Distribution
Fs 2
1/s2
2 F(n−1)(m−1)
F, outlier removed s2
1/s2
2 F(n−1)(m−1)
MAD MAD2
1/MAD2
2 F(n−1)(m−1)
Qn Q2
n1/Q2
n2 F(n−1)(m−1)
F, permutation s2
1/s2
2 Empirical
SD Diff, permutation s1−s2 Empirical
MAD Diff, permutation MAD1−MAD2 Empirical
Qn Diff, permutation Qn1−Qn2 Empirical
misclassiﬁcation errors in 1% of the cases. The results are presented in
Section 3.1.
2.5 Effect of preprocessing methods on a real dataset
Traditionally variability of gene expression among a group of samples is
treated as noise, and is to be eliminated by various transformation and
normalization procedures. This motivates the question: ‘how do different
preprocessing methods affect the discovery of DV genes?’. To address
this issue, we preprocessed a lung cancer dataset (Stearman et al., 2005)
using ﬁve different methods and compared the concordance among the ﬁve
lists of inferred DV genes. The ﬁve methods evaluated here are: MAS 5.0
(Affymetrix Inc., 2002), RMA (Irizarry et al., 2003), GCRMA (Wu et al.,
2004), FARMS (Hochreiter et al., 2006) and DFW (Chen et al., 2007). They
were selected based on their popularity and/or their superior performance in
the Affycomp II competition (Cope et al., 2004; Irizarry et al., 2006). We
used the standard R implementations of all of the preprocessing methods.
The raw data in CELﬁles were read, and were individually processed by the
ﬁve methods. As far as possible, default parameters were used, otherwise,
we used quantile normalization method with no background correction and
ignoredmismatchprobedata.Afterthedatawerepreprocessed,wethenused
the F-test procedure to rank the genes according to the P-values. The lower
the P-value, the more likely it is that the gene is differentially variable. This
step resulted in ﬁve ranked DV gene lists. Then for each pair of DV gene
lists, the 200 genes with the lowest P-values were selected to calculate the
concordance between two gene lists. Concordance between two lists (L1 and
L2)o fn genes is deﬁned as
concordance(n)=
|L1(n)∩L2(n)|
n
,
where Li(n) is the set of the n top-ranked genes in list Li. Concordance
measures the proportion of overlapping genes between two lists (Patterson
et al., 2006). If two methods have concordance of 0.5, it means only 50% of
the genes found in one list are also in the other list.
2.6 Power of the F-test
One question is ‘how many samples per group are required to recover all
true DV genes?’ We can address this problem by calculating the power of
the F-test using different numbers of samples. The statistical power of a
test is deﬁned to be the probability of rejecting the null hypothesis when the
alternativehypothesisisindeedtrue(=1−typeIIerrorrate).Thestatisticf is
distributedaccordingtoFn−1,m−1 underthenullhypothesis.Ifthealternative
hypothesis is true, f should be distributed according to k×Fn−1,m−1 where
k is the fold change in population variance, σ2
1/σ2
2. Therefore, the statistical
power of this test is a function of k, signiﬁcance level α, and the sample
sizes n and m. The power function is as follows:
power(k,α,n,m)=

P(k×Fn−1,m−1>F−1
n−1,m−1(1−α)) if k>1
P(k×Fn−1,m−1<F−1
n−1,m−1(α)) if 0<k<1
(1)
2.7 Analysis of real datasets
To demonstrate the general applicability of our approach in understanding
human diseases, we collected three Affymetrix datasets from the NCBI
Gene Expression Omnibus (GEO) database (Edgar et al., 2002) and one
Affymetrix dataset from the CardioGenomic project website of Harvard
Medical School (CardioGenomics, 2008). The details of the four datasets
are summarized in Table 4. All datasets were quantile normalized, followed
by probe-level summarization using DFW (Chen et al., 2007). The datasets
were tested for differential variability using our F-test-based procedure,
and differential expression by Welch’s two-sample t-test (Welch, 1947).
The resulting P-values were adjusted to control for false-discovery rate in
multiplecomparisonusingthemethodproposedbyBenjaminiandHochberg
(1995). A gene was judged as signiﬁcantly DV or DE if its corresponding
adjusted P was ≤0.05.
Furthermore, we looked for statistically over-represented gene ontology
(GO) terms associated with those DV genes using GOstat (Beissbarth and
Speed, 2004). GOstat employs a χ2-test or Fisher’s exact test to determine
if a GO term is signiﬁcantly over-represented in the set of genes. Again, the
resulting P-value for each GO term is adjusted for multiple comparisons by
the Benjamini and Hochberg procedure.
2.8 Differential coexpression analysis
For each of the four human disease datasets, we extracted the four subsets of
200 genes which exhibited the largest: (1) decrease in variability (DV dec.);
(2)increaseinvariability(DVinc.);(3)decreaseinexpression(DEdec.);and
(4) increase in expression (DE inc.) in diseased compared with non-diseased
individuals.Foreachsubsetof200genes,wecomputedaPearsoncorrelation
coefﬁcient, r, for each pair of genes in each of the ‘normal’samples and the
‘disease’ samples. A gene pair is positively coexpressed if its r>0.85, or
negatively coexpressed if its r<−0.85. If a set of genes is differentially
coexpressed, we expect the distribution of r in the ‘normal’ samples to be
different from the r distribution in the ‘disease’samples. Therefore, if DV or
DE is associated with change in DC, then we expect to observe a big change
in the distribution of r in the four 200-gene subsets in each human disease
dataset.
3 RESULTS
3.1 Comparison of differential variability tests
We compared eight differential variability tests using simulated
data. The results are shown in Table 2. For a good DV test
(at 0.01 signiﬁcance level), we expect it to have a false-positive
rate of 1% and a true-positive rate of 99%. In general, we ﬁnd
that the F-test with outlier removal (F, o.r.) and all permutation-
based tests are effective against false-positives. However, F-test
with outlier removal has a higher than expected false-negative
rate (i.e. it fails to identify at least 99% of the true DV genes).
Given the high true-positive rate of the F-test (without outlier
removal), it is probable that increasing the parameter r for the
IQR outlier removal step can increase the true-positive rate, though
compromising the false-positive rate. MAD and Qn consistently
produce higher than expected false-positive rates in all simulated
data. The permutation tests based on the difference of MAD (MAD
Diff, perm.) and difference of Qn (Qn Diff, perm.) have low
false-positive rates, but only moderately high true-positive rates.
F-statistic with permutation test (F, perm.) and the difference of
SDs (SD Diff, perm.) both perform reasonably well in terms of
true- and false-positive rates.
Since our study aims to investigate the biological relevance of
DV genes, we would like to avoid false positives as far as possible.
Therefore, a method with high precision (high true-positive rate
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Table 2. Comparison of the performance of differential variability detection methods using simulated datasets
DV Distribution F(%) F, o.r.(%) MAD(%) Qn(%) F, perm.(%) SD Diff, perm.(%) MAD Diff, perm.(%) Qn Diff, perm.(%)
No Normal 0.33 0.67 10 6.33 0.33 0 1 0.67
No Normal, 1 outlier 44.33 1 9 6.33 1.33 1 0.67 0.67
No Uniform 00 8.33 2 1.33 1.67 1 1.33
No Gamma 3 1 13.33 6.33 2 1.33 1 0.33
Yes Normal 100 81 97 99 99.33 99.33 87.33 87
Yes Normal, 1 outlier 78.67 78.67 99.33 99 55.33 55.67 76 78.67
Yes Uniform 100 95.33 97.33 100 100 100 87.33 81.33
Yes Gamma 95 49.67 49.67 38.67 89.33 90.67 14 4.67
The values represent the percentage of 300 genes that were identiﬁed as differentially variable (signiﬁcance level 0.01). All results that have low false-positive rates (<1%) or high
true-positive rates (>99%) are shown in bold.
Table 3. Concordance of the 200 most highly ranked DV genes (genes with
the lowest P-values) from the Stearman et al. (2005) dataset preprocessed
by ﬁve different preprocessing methods
DFW FARMS RMA GCRMA
MAS 5.0 0.460 0.450 0.395 0.295
GCRMA 0.395 0.460 0.515
RMA 0.650 0.680
FARMS 0.695
and low false-positive rate) is most suitable for our purpose. MAD
and Qn fail this criterion. Although all permutation-based tests
perform reasonably well, they are computationally very intensive,
particularly if we want to estimate P-value accurately (e.g. 1000
rounds of permutations result in P-value accurate to at most three
decimal places). Since F-test with outlier removal performs just as
well as the permutation-based tests, it is a preferable test. Further,
ﬁne tuning of the parameter r may result in a better true-positive
rate. Since the tuning of r is most likely dataset dependent, we do
not discuss this issue further here.
3.2 Effect of preprocessing methods on concordance of
DV identiﬁcation
The effect of microarray preprocessing methods on DV discovery
was investigated. Using a lung cancer microarray dataset (Stearman
et al., 2005), we compared the lists of DV genes discovered from
the dataset preprocessed by ﬁve procedures. The ﬁve sets of n=
200 most highly ranked DV genes were compared to determine
their concordance. Concordance between each pair of the ﬁve lists
is shown in Table 3. The results show that DV genes identiﬁed
by data preprocessed by RMA, FARMS and DFW are reasonably
concordant, while the results generated by MAS 5.0 preprocessed
data are generally quite different from others. This conclusion is
consistent irrespective of n used to calculate concordance (data not
shown).
3.3 Analysis of human disease datasets
We collected and analyzed four microarray datasets related to
human diseases (Table 4). The distribution of genes with signiﬁcant
increasing/decreasing DE or DV in the four datasets is shown in
Table 5. Despite the differences in the types of disease and sample
sizes, some general patterns emerge. First, we note that a much
smaller number of signiﬁcant DV genes are identiﬁed compared
to signiﬁcant DE genes. Second, the number of upregulated and
downregulated DE genes are mostly similar, while DV genes with
increased variability predominate in diseased patients. Third, there
is a positive correlation between DV and DE (i.e. up-regulated DE
genes are likely to have increased variability).
Based on the above observations, one may suspect that the
observed changes in expression variability are simply artifacts of
some non-linear relationships between mean expression level and
variability. More speciﬁcally, we want to know if the observed
variability is due to stochastic noise in RNAproduction. We address
this question by studying the differential coexpression patterns
among the 200 most highly ranked DVand DE genes for each of the
four human disease datasets. For each 200-gene set, we computed a
Pearsoncorrelationcoefﬁcientforeachofthe(200×199)/2=19900
pairs of genes, and accordingly labeled each gene pair as negatively,
positively or not coexpressed (results shown in Table 6). In all four
datasets,differentialcoexpressionappearstobepositivelycorrelated
with differential variability. This is particularly remarkable in the
four DV inc. gene lists, in which increase in variability correlates
with a vast increase in coexpressed gene pairs. Unexpectedly, we
also observe an association between decrease in mean expression
and increase in coexpression, while increase in mean expression
does not appear to correspond to a change in coexpression. As an
example, the distributions of pairwise gene coexpression of the DV
and DE genes found in the CardioGenomics dataset are shown in
Figure 2. We note the extreme difference in coexpression patterns
betweenthenormalanddiseasedpatientsintheDVinc.data(Fig.2b
and 2f, respectively). Whereas for normal individuals fewer than
1% of the gene pairs are classiﬁed as signiﬁcantly coexpressed,
over 60% of the gene pairs become signiﬁcantly coexpressed in
the diseased patients (Table 6).
3.4 Biological signiﬁcance of DV genes
Some of the signiﬁcant DV genes discovered from the four human
disease datasets are presented inTable 7.The biological signiﬁcance
of these DV genes and/or associated over-represented GO terms are
described in the following subsections.
3.4.1 Stearman dataset The Stearman et al. (2005) study
originally investigated the conservation of gene expression patterns
between human and mouse in lung adenocarcinoma. In their study,
39 human microarrays were constructed from tumour tissues and
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Table 4. Summary of the microarray dataset used
Dataset Disease nm Probes Platform |DV|| DE|| DV ∩ DE|
Stearman et al. (2005) Lung adenocarcinoma 19 20 12625 HG-U95Av2 1292 4668 854
Haslett et al. (2002) Duchenne muscular dystrophy 12 12 12625 HG-U95Av2 12 1567 12
Hong et al. (2007) Colorectal cancer 10 12 54675 HG-U133 Plus 2.0 35 5118 27
CardioGenomics Dilated cardiomyopathy 14 27 54675 HG-U133 Plus 2.0 248 10532 126
All datasets were generated from Affymetrix arrays. n is the number of arrays from non-diseased samples and m is the number of array from diseased samples. |DV|, |DE| and
|DV ∩ DE| represent the number of DV genes, DE genes and genes that are both DE and DV, respectively.
Table 5. Distribution of genes with signiﬁcant (P≤0.05) increasing (inc.), decreasing (dec.) or non-signiﬁcant (n.c.) DE or DV in the four human disease
datasets
(a) Stearman (b) Haslett (c) Hong (d) CardioGenomics
DV
dec. n.c. inc.
DE
dec. 18 1815 259 2092
n.c. 10 7519 428 7957
inc. 1 1999 576 2576
29 11333 1263
DV
dec. n.c. inc.
DE
dec. 0 677 0 677
n.c. 0 11058 0 11058
inc. 0 878 12 890
0 12613 12
DV
dec. n.c. inc.
DE
dec. 1 2792 9 2802
n.c. 0 49549 8 49557
inc. 0 2299 17 2316
1 54640 34
DV
dec. n.c. inc.
DE
dec. 16 5009 7 5032
n.c. 44 44021 78 44143
inc. 1 5397 102 5500
61 54427 187
Table 6. Relationship between DE, DV and DC
Dataset Patterns Normal Disease
Neg. Pos. Neg. Pos.
Stearman
DV dec. 0 149 1 16
DV inc. 0 2 49 183
DE dec. 0 38 0 512
DE inc. 1 11 0 58
Haslett
DV dec. 49 111 19 33
DV inc. 19 21 140 382
DE dec. 11 39 25 76
DE inc. 6 144 2 379
Hong
DV dec. 44 56 29 25
DV inc. 65 86 324 4356
DE dec. 35 176 1 1528
DE inc. 17 404 0 290
CardioGenomics
DV dec. 78 484 0 1
DV inc. 6 82 706 12207
DE dec. 1 68 0 761
DE inc. 5 32 0 43
The top ranking 200 genes with increasing/decreasing DV/DE are tested for DC. neg.
= negatively coexpressed (r<−0.85), pos. = positively coexpressed (r>0.85).
adjacent (normal) tissues from 10 lung adenocarcinoma patients,
run in duplicate. To simplify the analysis, we treated those technical
replicates as biological replicates. Nearly 1300 DV genes were
identiﬁed, and about 66% of them are also differentially expressed
(Table 5). Signiﬁcantly over-represented GO terms with DV genes
with lower variability in cancer patients include negative regulation
of cellular process (GO:0048523, P=0.0569), negative regulation
of apoptosis (GO:0043066, P=0.0588) and cell differentiation
(GO:0030154, P=0.0752). Signiﬁcantly over-represented GO
terms associated with DV genes with increased variability include
regulation of transcription (GO:0045449, P=0.0009), spindle
organization and biogenesis (GO:0007051, P=0.0029) and cell–
cell signaling (GO:0007267, P=0.0252). At the gene level, we
found a number of genes related to immune response, cell growth
and oncogenesis (Table 7 and Fig. 3). A number of DV genes are
not differentially expressed, including STARD7, IFI16, IGF2 and
MTSS1 (Fig. 3). They demonstrate that biologically relevant genes
can have differential variability without differential expression.
3.4.2 Haslett dataset The Haslett et al. (2002) study compared
the expression proﬁles of 12 normal skeletal muscles with muscle
samples from 12 Duchenne muscular dystrophy (DMD) patients. In
this dataset, only 12 genes are deemed signiﬁcantly DV and all of
thesegeneshaveelevatedvariabilityandaverageexpressionlevelin
DMDpatients.Thetop-rankingDVgene,SPP1(osteopontin),isalso
upregulated and was validated by reverse transcriptase–polymerase
chainreactionbyHaslettetal.(2002).SPP1isamacrophageproduct
that enhances synthesis and turnover of extracellular matrix (Porter
et al., 2002), and is induced by free phosphates in damaged tissues
(Beck et al., 2000). Therefore, the variable upregulation of SPP1
expression in DMD patients might be a result of varying response
to muscle damage.
3.4.3 Hong dataset The Hong et al. (2007) study compared the
expression proﬁle of 10 normal tissue samples and 12 colorectal
cancer samples. We found one gene (G6PC) with decreased
variabilityand34geneswithincreasedvariabilityincancerpatients.
Among these DV genes, many of them (FOSB, CYR61, EGR1,
FIGF) were also described by Hong et al. (2007) as signiﬁcantly
upregulated. Our analysis, therefore, show that these genes are
not only upregulated in cancer patients, but that the degree
of upregulation also varies signiﬁcantly compared to expression
variability among non-diseased individuals.
3.4.4 CardioGenomics dataset The CardioGenomics data
consists of expression proﬁles from left ventricular muscle of 14
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Fig. 2. Distribution of pairwise correlation coefﬁcient among the 200 top-ranking increasing/decreasing DV and DE genes in the CardioGenomics dataset.
There is a marked increase in coexpression in proﬁles with higher variability.
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Fig. 3. Some typical genes with statistically signiﬁcant DV in the Stearman dataset. The expression value is sorted within each group independently of other
genes to better visualize the variability among samples. IL1RL1, IL6 and STARD7 are examples of genes with decreased variability in lung cancer patients.
ADCY9, IFI16 and IGF2 are examples of genes with increased variability in lung cancer patients.
non-failing donor hearts and 27 end-stage failing hearts (due to
dilated cardiomyopathy). We identiﬁed 248 DV genes in which
about half of them are also DE. A number of these DV genes are
known to be involved in heart failure (Table 7). LIMS1 displays
decreased variability and decreased expression in the failing hearts
compared with non-failing hearts. The IPAP1 complex, in which
LIMS1 is a member along with ILK and α-parvin proteins, is
involved in cardiac hypertrophy and apoptosis (Chen et al., 2005).
Loss of tight regulation of an integral member of the IPAP1
complex may be involved in the inability of the failing heart to
compensate via hypertrophy for its reduced contractility, or may
in fact promote cardiac dysfunction by leading to the increased
loss of cardiomyocytes via apoptosis. This would in turn increase
the load on the remaining cardiomyocytes and exacerbate cardiac
dysfunction. MCM4 displays decreased variability and increased
mean expression in failing hearts compared with non-failing hearts.
Since MCM4 is a protein required for cell division (Bailis et al.,
2008), these changes in RNA abundance could reﬂect an increase
in cell division in heart failure that is not a consistent feature of
hearts from donors, who at the time of death may or may not
have been in a state of cardiac health that required cardiomyocyte
proliferation. The loss of expression variability of SMAD3 in
the failing hearts compared with non-failing hearts implies a loss
of transcriptional regulation of this gene. SMAD3 is involved
in transforming growth factor-β mediated interstitial ﬁbrosis in
response to cardiac injury (Bujak et al., 2007). Dysfunction of this
pathway may be involved in the progression to heart failure due to
failing hearts losing the ability to respond appropriately to damage.
The ephrin receptor, EPHB4, seems to be involved in regulating
embryonic stem cell differentiation into several cardiac tissue
types including cardiomyocytes and endothelial cells (Wang et al.,
2004). Therefore, the observed increase in variability of EPHB4
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Table 7. Some signiﬁcant DV genes discovered in the four human disease datasets
DV DE
Dataset Gene Description adjusted P adjusted P
Stearman
IL1RL1* Interleukin 1 receptor-like 1 0.000220 9.64E-05  
IL6* Interleukin 6 (interferon, β 2) 0.004523 0.001240  
IL8RA* Interleukin 8 receptor, α 0.006749 0.000307  
STARD7* START domain containing 7 0.020005 0.770919
JUNB* Jun B proto-oncogene 0.048983 0.002005  
ADCY9 Adenylate cyclase 9 8.45E-07 0.002343  
IFI16 Interferon, γ-inducible protein 16 0.000117 0.665773
IGF2 Insulin-like growth factor 2 (somatomedin A) 0.020126 0.792114
MTSS1 Metastasis suppressor 0.015878 0.550911
Haslett
SPP1 Secreted phosphoprotein 1 4.15E-05 0.002375  
PLA2G2A Phospholipase A2, group IIA (platelets, synovial ﬂuid) 0.000546 0.003778  
TIMP1 TIMP metallopeptidase inhibitor 0.019086 0.000242  
PDIA3 Protein disulﬁde isomerase family A, member 3 0.030963 0.008129  
FRZB Frizzled-related protein 0.030963 0.006435  
MYL4 Myosin, light chain 4, alkali; atrial, embryonic 0.043187 0.002082  
Hong
G6PC* Glucose-6-phosphatase, catalytic subunit 0.046837 0.014506  
FOSB FBJ murine osteosarcoma viral oncogene homolog B 0.000436 0.001841  
CYR61 Cysteine-rich, angiogenic inducer, 61 0.000436 0.000151  
EGR1 Early growth response 1 0.009421 0.001968  
FIGF c-Fos induced growth factor (vascular endothelial growth factor D) 0.009421 0.067034
MCAM Melanoma cell adhesion molecule 0.031857 0.005266  
CardioGenomics
LIMS1* LIM and senescent cell antigen-like domains 1 0.005508 0.011308  
MCM4* Minichromosome maintenance complex component 4 0.008197 0.040694  
SMAD3* SMAD family member 3 0.009093 0.079661
EPHB4 EPH receptor B4 0.000965 0.243504
TRPC4 Transient receptor potential cation channel, subfamily C, member 4 0.005356 0.057685
ZBP1 Z-DNA-binding protein 1 0.033411 0.111145
These DV genes are selected based on biological relevance to the disease under consideration.All genes marked with asterisk have decreased expression variability, while unmarked
genes have increased variability in diseased patients. The adjusted P-values for DV and DE are shown. Signiﬁcant up- and downregulation are marked next to the DE P-value by
up- and down-arrow, respectively.
expression in failing hearts may reﬂect varying patient responses
to heart failure, some with greater or lesser compensation by repair
from recruited stem cells. In mouse models of cardiomyopathy
(Nakayama et al., 2006) and cardiac hypertrophy (Kuwahara et al.,
2006), TRPC4 expression has been shown to be elevated. TRPC4
may play a role as a store-operated cation channel, mediating
calcium ion entry into the cell in times of SR calcium depletion
(Dietrich et al., 2007). Here we show that the variability of TRPC4
is higher in failing hearts compared with non-failing hearts. Though
the effect of such differential variability in human heart failure is
unknown at this time, our results are consistent with the common
observation of abnormal calcium handling in heart failure in mouse
models.
4 DISCUSSION
In this article, we discuss an important but often neglected pattern
in large gene expression proﬁle datasets: DV. As demonstrated
by the four human disease datasets we analyzed, it is clear
that: (1) statistically signiﬁcant DV genes do exist and they are
biologically relevant; (2) both increase and decrease of variability
in diseased patients are possible, although increase in variability
seems to be more common; (3) expression variability is positively
correlated with the degree of gene coexpression. As far as we are
aware, this is the ﬁrst study that establishes relationships between
inter-sample expression variability, mean expression level and
coexpression.
So what is the biological basis for differential variability? We
believe it is due to the dynamics of the cellular regulatory network.
Based on our results, we hypothesize that differential variability
of a gene is caused by the loss or gain of a set of uniformly
activating or inhibiting transcription factors (or gene expression
regulators in general). For example, switching on an activator
can raise the expression level of all its downstream genes, which
causes an increase in coexpression. However, since the activity
of the regulators may vary among individuals, the responsiveness
of the downstream genes may vary as well. This causes an
increased expression variability across samples. Therefore, the
consequences of switching on an upstream activator include higher
average expression, and more variable yet coordinated expression
across samples, which matches our observations (Tables 5 and 6).
Therefore, perhaps DV is a good predictor of DC among genes.
Then how does decrease in mean expression correlate with
increase in coexpression? We attribute this pattern to loss of a
largenumberofpositiveregulatorsoftranscription.Theseactivating
transcription factors each perhaps regulate a group of genes that are
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Fig. 4. The power curve for the F-test based on different signiﬁcance levels
(sig.) and sample sizes. This power curve assumes the true population
variance of the ‘disease’ samples is ﬁve times higher than those from the
‘normal’ group.
coregulatedbyothertranscriptionfactors,intheformofamultiinput
module (Alon, 2007). When a number of such regulators are lost,
all the downstream genes will suffer a loss of expression, but also
as the number of regulators is markedly reduced, the downstream
genes experience much more similar regulatory input, and therefore
their expression becomes more correlated. However, if the reverse
happens and these transcription factors increase their expression,
the patterns of coexpression will not be affected, so the reverse
situation of decreased coexpression would not occur in association
with increased expression, which was observed in our result.
Although we are aware of possible sources of variability from the
data collection of experimental procedures, we still have conﬁdence
about our conclusions because of the strong and consistent
correlationbetweenDVandDCacrossallfourindependentdatasets,
and that some signiﬁcant DV genes are known to be implicated in
pathogenesis.
Compared to the number of DE genes, the number of signiﬁcant
DV genes is small. Also, the number of signiﬁcant DV genes
seems to increase as the number of samples per group increases. To
investigatethiseffect,wegeneratedpowercurves,usingEquation1,
for the F-test based on different signiﬁcance levels and sample sizes
(here we assume a balanced number of samples in each group, i.e.
n=m). The power curves (Fig. 4) assume that the true population
variance of the ‘disease’ samples is ﬁve times higher than those
from the ‘normal’group. Since most of our datasets have fewer than
20 samples per group, at signiﬁcance level of 10−5, the statistical
power is <20% (ı.e. <20% of the true DV genes are discovered by
our procedure). This suggests that there are potentially a lot more
signiﬁcant DV genes present in our real datasets that cannot be
recovered, due to the small sample size. In general, the larger the
sample size, the higher the power, which should be made possible
due to the continuous reduction of cost of running a microarray
experiment.
WhencomparingtheF-testwithoutlierremovalwithotherrobust
variants, our procedure was shown to have a low false-positive rate.
Since no computationally intensive permutation test is required, our
test runs relatively quickly and is therefore suitable for large-scale
explorative analysis. Once DV genes are extracted, we may then
perform permutation tests to obtain an empirical P-value for each
gene if desired. Here we only considered differential variability tests
for two-group comparisons because this is the simplest and most
common type of experimental data. Such a test could be extended
to general multi-group comparison by using an extension to F-test
such as Bartlett’s test or Levine’s test.
We found that the set of signiﬁcant DV genes does vary when
different preprocessing methods are used.The concordance between
preprocessing methods varies between ∼30% and ∼70%. We
subsequently chose DFW to preprocess all of our real data because
of its superior accuracy (Chen et al., 2007), and its relatively
high concordance with two other reasonably reliable preprocessing
methods, FARMS and RMA. This result gives us a baseline for
assessinghowreliableaDVanalysisis.Forexample,ifweidentiﬁed
100 DV genes in a dataset preprocessed by DFW, we can estimate
that about 65% of these genes would also be found if the data were
preprocessed by RMA or FARMS.
Prieto et al. (2006) developed an algorithm based on a variant of
the mean squared residue originally developed for data biclustering
(Cheng and Church, 2000) to ﬁnd sets of genes that are deregulated
inexpressionproﬁlesofdiseasedpatients.Theydeﬁnedderegulation
as an increase in expression variability for a set of genes. Therefore,
their deﬁnition implies that a set of genes can be deregulated due to
DC (when the set of genes lose coexpression in the diseased group),
DE (when some genes are upregulated and some downregulated)
or DV (when all genes have increased variability in the diseased
state). Their method cannot distinguish individual genes that are
DE, DV or DC, which generally have different biological meaning.
Further, their method does not consider the case where expression
variability is decreased in the diseased samples, and may therefore
exclude some candidate genes from being detected.
In fact, our deﬁnition of differential variability deliberately
includes both increase and decrease of variability between two
groups of samples. Many existing methods only look for genes that
have more unpredictable expression patterns because they associate
these altered expression patterns with deregulation, e.g. Kostka and
Spang (2004) and Prieto et al. (2006) considered the problem of
increase in deregulation in diseased samples. However, we found
that decrease in variability is also possible in human diseases.
Further, as exempliﬁed in the CardioGenomics dataset (Fig. 2),
the set of 200 most highly ranked DV genes has dramatically
higher coexpression in the diseased samples compared to the normal
samples (Table 6). This result shows that increase in variability
does not imply deregulation, but in fact it probably means a gain of
coregulation in the diseased samples. Since the Pearson correlation
coefﬁcient should be scale-invariant, the observed relationship
between DV and DC is likely a biological relationship and not a
technical artifact.
5 CONCLUSION
We have described DV analysis of gene expression and its
application in searching for disease-related genes in human diseases
using microarray data. We found that changes in expression
variability are associated with changes in coexpression patterns.
Therefore, differential variability is potentially an important
manifestationofchangesingeneregulation.Asaresult,DVanalysis
cancomplementtraditionalanalysisbasedondifferentialexpression
anddifferentialcoexpression.Aslargerdatasetsarebeinggenerated,
we anticipate our differential variability analysis to become much
more applicable.
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